Other substances

Aloxistatin

A cysteine protease inhibitor.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Experimental

2
 Supporting references
0
 Contradictory references
1
 AI-suggested references
20
 Clinical trials

General information

Aloxistatin is an irreversible cysteine protease inhibitor. It blocks platelet aggregation (NCIt). Aloxistatin was shown to inhibit cathepsin L activity in cell culture, which was suggested to explain its inhibitory effect on SARS-CoV-2 infection in a mouse model (Zhao et al., 2021).

Aloxistatin on PubChem
Aloxistatin on Wikipedia

Synonyms

E64d; Loxistatin; EST

 

Structure image - Aloxistatin

CCOC(=O)[C@@H]1[C@H](O1)C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C

Supporting references

Link Tested on Impact factor Notes Publication date
Identification of potential treatments for COVID-19 through artificial intelligence-enabled phenomic analysis of human cells infected with SARS-CoV-2
Preprint 		human renal cortical epithelial cells

strong effect

 Apr/23/2020
Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development
Cathepsin L Small molecule Animal model In vitro Mechanism 		Huh-7 cells; hACE2-mice; (VSV) SARS-CoV-2 Spike-pseudotyped virus 13.49

Aloxistatin inhibited SARS-CoV-2 pseudovirus infection without significant cytotoxicity in vitro. It was shown to decrease cathepsin L activity in the treated cells. The compound suppressed the infection in a mouse model.

 Mar/27/2021

AI-suggested references

Link Publication date
TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells
Jul/23/2020

Clinical trials

ID Title Status Phase Start date Completion date
NCT04340479 The Use of Ultrasound in Establishing COVID-19 Infection as Part of a Trauma Evaluation Completed Jul/30/2020 Sep/01/2021
  • Alternative id - 20-0751
  • Interventions - Diagnostic Test: Ultrasound lung imaging as part of FAST+ evaluation
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Children's Hospital Colorado, Aurora, Colorado, United States
  • Study designs - Observational Model: Cohort|Time Perspective: Prospective
  • Enrollment - 53
  • Age - Child, Adult, Older Adult
  • Outcome measures - Correlation of FAST+ pulmonary findings with active COVID infection|Description of additional ancillary findings of the FAST+ examination among infected and non-infected patients
NCT04853069 Oestrogen Treatment for COVID-19 Symptoms Not yet recruiting Phase 2 May/17/2021 Mar/31/2022
  • Alternative id - MRC-05-099
  • Interventions - Drug: Transdermal estradiol gel
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Hamad Medical Corporation, Doha, Qatar
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 2000
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Evidence of disease progression for mild cases|Evidence of disease progression in hospitalised patients (moderate and severe cases)|Hospital mortality|Duration of hospital admission|Admission to ICU/ HDU facility|Need for renal replacement therapy|Ventilation|Time to being fit for hospital discharge
NCT04701905 The Offer of Neurosurgery Care in the Grand Est of France During the Health Crisis Linked to Covid-19 Recruiting Apr/30/2020 Apr/30/2021
  • Alternative id - 7780
  • Interventions -
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Department of Neurosurgery - Strasbourg University Hospitals, Strasbourg, France
  • Study designs - Observational Model: Case-Only|Time Perspective: Retrospective
  • Enrollment - 450
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Retrospective analysis of the management of neurosurgical pathologies in a health crisis situation of the Covid-19 pandemic
NCT04366206 Factors Associated With Clinical Outcomes in Patients Hospitalized for Covid-19 in GHT-93 Est Recruiting Mar/14/2020 Jul/31/2020
  • Alternative id - GHTRB-2020-01
  • Interventions -
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Centre Hospitalier Intercommunal Robert Ballanger, Aulnay-sous-Bois, France|Groupe Hospitalier Pitie Salpetriere, Paris, France
  • Study designs - Observational Model: Cohort|Time Perspective: Prospective
  • Enrollment - 143
  • Age - Child, Adult, Older Adult
  • Outcome measures - Composite of death and mechanical ventilation|Need for mechanical ventilation|Death|Acute kidney injury|Acute respiratory distress syndrome|Cardiac arrhythmia and conduction disorder|60-days mortality|60-days mechanical ventilation
NCT04757870 Macro-scale Estimators of Covid-19's Worldwide Cases and Deaths Not yet recruiting Mar/01/2021 Dec/31/2021
  • Alternative id - KCU_16022021
  • Interventions - Other: frequency
  • Study type - Observational
  • Study results - No Results Available
  • Locations -
  • Study designs - Observational Model: Other|Time Perspective: Other
  • Enrollment - 1790
  • Age - Child, Adult, Older Adult
  • Outcome measures - Occurence|Mortality
NCT04359329 Estrogen Patch for COVID-19 Symptoms Terminated Phase 2 Apr/20/2020 Jul/30/2020
  • Alternative id - SBU-EstrogenPatch-COVID19
  • Interventions - Drug: Estradiol patch
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Stony Brook University Hospital, Stony Brook, New York, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 2
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Rate of Hospitalization|Rate of Transfer to Intensive Care Unit|Rate of Intubation|Rate of Death
NCT05032950 Drug-Drug Interaction Study to Estimate the Effect of PF-07321332/Ritonavir and Ritonavir on Midazolam in Healthy Participants Completed Phase 1 Sep/17/2021 Dec/09/2021
  • Alternative id - C4671013|2021-003590-62
  • Interventions - Drug: Midazolam|Drug: PF-07321332/ritonavir + Midazolam|Drug: Ritonavir + Midazolam
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Brussels Clinical Research Unit, Brussels, Bruxelles-capitale, Région DE, Belgium
  • Study designs - Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science
  • Enrollment - 12
  • Age - 18 Years to 60 Years   (Adult)
  • Outcome measures - Maximum Observed Plasma Concentration (Cmax) of midazolam when administered alone|Cmax of midazolam when administered with PF-07321332/ritonavir|Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of midazolam when administered alone|AUCinf of midazolam when administered with PF-07321332/ritonavir|Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of midazolam when administered alone|AUClast of midazolam when administered with PF-07321332/ritonavir|Assessment of Participants With Treatment-Emergent Adverse Events (TEAEs) of PF-07321332/Ritonavir|Assessment of Participants With Clinically Significant Change From Baseline in Laboratory Abnormalities of PF-07321332/Ritonavir|Assessment of Participants With Clinically Significant Change From Baseline in Vital Signs of PF-07321332/Ritonavir|Number of Participants With Clinically Significant Change in Electrocardiogram (ECG) Findings of PF-07321332/Ritonavir|Cmax of midazolam when administered with ritonavir|AUCinf of midazolam when administered with ritonavir|AUClast of midazolam when administered with ritonavir|Apparent Oral Clearance (CL/F) of midazolam when administered alone|CL/F of midazolam when administered with PF-07321332/ritonavir|Apparent Oral Volume of Distribution (Vz/F)) of midazolam when administered alone|Vz/F of midazolam when administered with PF-07321332/ritonavir|Time to Cmax (Tmax) of midazolam when administered alone|Tmax of midazolam when administered with PF-07321332/ritonavir|Plasma Decay Half-Life (t1/2) of midazolam when administered alone|t1/2 of midazolam when administered with PF-07321332/ritonavir
NCT04408027 Mental Health Support for SickKids Children and Families During COVID-19 Using Established eHealth Interventions Recruiting Not Applicable Jun/01/2020 Jun/01/2022
  • Alternative id - REB1000070362
  • Interventions - Behavioral: Virtual-Care Cognitive Behavioural Therapy
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - The Hospital for Sick Children (SickKids), Toronto, Ontario, Canada
  • Study designs - Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 20
  • Age - 12 Years to 17 Years   (Child)
  • Outcome measures - Participation Barriers|Number of Eligible Participants|Number of Participants Approached|Number of Participants Consented|Rates of Refusal|Reasons for Refusal|Number of Sessions Completed in Total|Adherence Index|Amount of time (in weeks) to complete the intervention|Intervention Acceptability|Participant Satisfaction|Working Alliance Inventory after First Intervention Session|Working Alliance Inventory after Sixth Intervention Session|Working Alliance Inventory after Final Intervention Session|Family Impact During a Pandemic at Baseline|Family Impact During a Pandemic after Final Intervention Session|Efficacy of Virtual-Care CBT Intervention|Clinician Virtual Care Experience
NCT04539626 Estrogen Therapy in Non-severe COVID-19 Patients Recruiting Not Applicable Oct/01/2020 Dec/01/2022
  • Alternative id - 03
  • Interventions - Drug: Estrogen Therapy
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - CMN "20 de Noviembre", Mexico City, Benito Juárez, Mexico
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 60
  • Age - 18 Years to 70 Years   (Adult, Older Adult)
  • Outcome measures - Clinical improve to estrogen therapy in non-severe COVID-19 patients Clinical improve to estrogen therapy in non-severe COVID-19 patients|Clinical improve to estrogen therapy in non-severe COVID-19 patients|Symptomatic improve to estrogen therapy in non-severe COVID-19 patients|Biochemical improve to estrogen therapy in non-severe COVID-19 patients
NCT05069389 Registry of Management Strategies for Patients With COVID-19 in Healthcare Establishments Recruiting Jun/02/2020 Dec/31/2022
  • Alternative id - EDS_2020_HOPICOV
  • Interventions - Other: Data collection
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Hospital Center Emile Roux, Le Puy-en-Velay, France
  • Study designs - Observational Model: Cohort|Time Perspective: Retrospective
  • Enrollment - 2071
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Describe management strategies implemented by healthcare establishments for patients with covid-19, depending on the evolution of scientific knowledge and recommendations for specific treatments.|Describe management strategies to take care depending on the patient|Compare patients' clinical course who received different management strategies|Evaluate the cost of the care|Evaluate the effectiveness of the care
NCT04531748 Selective Estrogen Modulation and Melatonin in Early COVID-19 Withdrawn Phase 2 Dec/01/2021 Sep/01/2022
  • Alternative id - 20-842
  • Interventions - Drug: Toremifene|Drug: Melatonin|Other: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations -
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 0
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Peak increase in COVID-19 Sign and Symptom score|Nadir Oxygen Saturation|Peak Heart Rate|Time to COVID-19 Sign and Symptom score resolution|Time to WHO 7-point ordinal scale score of 3 or higher
NCT02081326 Repeat BCG Vaccinations for the Treatment of Established Type 1 Diabetes Active, not recruiting Phase 2 Jun/01/2015 Jul/01/2027
  • Alternative id - 2013P002633
  • Interventions - Biological: Bacillus Calmette-Guérin|Biological: Saline injection
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Immunobiology Labs CNY 149, Charlestown, Massachusetts, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment
  • Enrollment - 150
  • Age - 18 Years to 65 Years   (Adult, Older Adult)
  • Outcome measures - Change in HbA1c values in juvenile onset type 1 diabetics|Insulin use in juvenile onset type 1 diabetics (AOO<21 years)|Endogenous insulin levels in the blood in juvenile onset type 1 diabetics (AOO<21 years)|Autoimmunity in juvenile onset type 1 diabetes (AOO<21 years)
NCT04573764 Acute Effects of Oral Ketone Ester on Cardiac Function in Patients With COVID-19 Recruiting Not Applicable Feb/01/2021 Jan/01/2022
  • Alternative id - H-20021500
  • Interventions - Dietary Supplement: D-beta-hydroxybutyrate-(R)-1,3 butanediol monoester|Dietary Supplement: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Bispebjerg Hospital, Copenhagen, Please Select, Denmark
  • Study designs - Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment
  • Enrollment - 12
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Left Ventricular ejection fraction|Global longitudinal strain|Cardiac output|Peripheral blood oxygen saturation|Venous blood oxygen saturation|Urine creatinine clearance
NCT04801836 Estetrol (E4) for the Treatment of Patients With Confirmed SARS-COV-2 Infection Active, not recruiting Phase 2 Nov/19/2020 Aug/05/2022
  • Alternative id - MIT-Co001-C101|2020-003403-33
  • Interventions - Drug: Estetrol monohydrate 15 mg|Drug: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - ERASME Hospital, Brussels, Belgium|CHR Citadelle, Liège, Belgium|Koranyi National Institute of Pulmonology, Budapest, Hungary|University of Pecs Medical Center, Pécs, Hungary|University of Szeged Medical Center, Szeged, Hungary|Szent Borbala Korhaz, Tatabánya, Hungary|Wojewódzki Szpital Specjalistyczny w Białej Podlaskiej Oddział Kardiologiczny Pododdział Kardiologii Zachowawczej, Biała Podlaska, Poland|Zespół Opieki Zdrowotnej w Bolesławcu Oddział Chorób Wewnętrznych, Boleslawiec, Poland|Arion Med. Sp z o.o. Zespół Opieki Zdrowotnej w Gostyninie Oddział Chorób Wewnętrznych, Gorzewo, Poland|Samodzielny Publiczny Zakad Opieki Zdrowotnej w Pulawach Oddział Obserwacyjno-Zakaźny, Puławy, Poland|Samodzielny Publiczny Zespół Zakładów Opieki Zdrowotnej w Staszowie Oddział Chorób Wewnętrznych, Staszów, Poland|Wielospecjalistycznego Szpitala im. J. Strusia z Zakładem Opiekuńczo - Leczniczym SP ZOZ Oddział Chorób Wewnętrznych, Szczecin, Poland|Szpital Matki Bożej Nieustającej Pomocy w Wołominie Oddział Chorób Wewnętrznych, Wołomin, Poland|Wojewódzki Szpital Specjalistyczny im. J. Gromkowskiego I Oddział Chorób Zakaźnych, Wrocław, Poland|City Clinical Hospital #15 n.a. Filatov, Moscow, Russian Federation|State budgetary healthcare institution of Moscow "City Clinical Hospital No 52 of the Department of Healhcare of Moscow", Moscow, Russian Federation|State Budgetary Healthcare Institution "Clinical Infectious Disease Hospital No. 1 of the Moscow City Health Department", Moscow, Russian Federation|Saint-Petersburg state budgetary healthcare institution "Clinical infectious hospital n.a. S.P. Botkin", Saint Petersburg, Russian Federation|City Hospital #15, Saint Petersburg, Russian Federation|Saint-Petersburg state budgetary healthcare institution "Pokrovskaya City Hospital", Saint Petersburg, Russian Federation|Saint-Petersburg state budgetary healthcare institution "Alexandrovskaya City Hospital", Saint-Petersburg, Russian Federation|Saint-Petersburg state budgetary healthcare institution "City hospital No 40 of resort region", Sestroretsk, Russian Federation|Budgetary healthcare institution of Voronezh Region "Voronezh regional clinical hospital", Voronezh, Russian Federation|State budgetary healthcare institution of the Yaroslavl Region "Yaroslavl regional clinical hospital of the war veterans - international center for health problems of aged people "Healthy longevity", Yaroslavl, Russian Federation|State budgetary healthcare institution of Moscow Region "Zhukovskaya City Clinical Hospital", Zhukovskiy, Russian Federation
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 162
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Percentage of participants who have recovered at Day 28|Number of participants reaching a score of ≥6 on the WHO (0-10) scale at Day 28|Time to recovery|SARS-CoV-2 viral load|Number of participants with AEs, SAEs, AESIs, SARs, SUSARs and Laboratory abnormalities as a measure of safety
NCT05005312 Study to Estimate the Effects of Hepatic Impairment on the Pharmacokinetics (PK) of PF-07321332 Completed Phase 1 Aug/31/2021 Dec/07/2021
  • Alternative id - C4671010
  • Interventions - Drug: PF-07321332|Drug: Ritonavir
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Orange County Research Center, Tustin, California, United States|Prism Research LLC dba Nucleus Network, Saint Paul, Minnesota, United States
  • Study designs - Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science
  • Enrollment - 17
  • Age - 18 Years to 75 Years   (Adult, Older Adult)
  • Outcome measures - Maximum observed plasma concentration (Cmax) for PF-07321332|Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Last Measurable Time (AUClast) for PF-07321332|Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) for PF-07321332|Incidence of Treatment Emergent Adverse Events|Incidence of Abnormal ECGs|Incidence of Abnormal Vital Signs|Incidence of Abnormal Laboratory Values
NCT04865029 Estradiol and Progesterone in Hospitalized COVID-19 Patients Recruiting Phase 2 Jul/22/2021 May/01/2022
  • Alternative id - 2020-939
  • Interventions - Other: Placebo injection and placebo pill|Drug: Estradiol Cypionate 5 MG/ML|Drug: Progesterone 200 MG Oral Capsule
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Tulane University Medical Center, New Orleans, Louisiana, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 120
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - The proportion of patients who achieve scores 1 or 2 on the 9-point World Health Organization (WHO) ordinal scale through day 28.|Length of hospital stay|Readmission|Duration of mechanical ventilation|Time of death|Cause of death|Change in biological markers ferritin, procalcitonin and troponin|Change in biological markers C-reactive protein and D-Dimer|Change in hypercoagulability marker fibrinogen|Change in tissue injury markers ALT, AST and LDH|Change in inflammation marker neutrophil:lymphocyte ratio|Grade 3 and 4 adverse events occurrence|Serious adverse events occurrence
NCT04844346 Plant Stanol Esters and COVID-19 Vaccination Response Terminated Not Applicable Apr/22/2021 Jan/11/2022
  • Alternative id - METC 21-013
  • Interventions - Dietary Supplement: Plant stanol mini drinks|Dietary Supplement: Placebo mini drinks|Biological: COVID-19 vaccine
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Maastricht University Medical Center, Maastricht, Limburg, Netherlands
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention
  • Enrollment - 48
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Vaccine specific antibody titers|Immune parameters (1)|Immune parameters (2)|Leukocyte count|Leukocyte differential count|Fasted metabolism (1)|Fasted metabolism (2)|Fasted metabolism (3)|Anthropometry (1)|Anthropometry (2)|Anthropometry (3)|Anthropometry (4)|Anthropometry (5)|Diet|Diary outcomes (1)|Diary outcomes (2)|Diary outcomes (3)
NCT04487886 Duvelisib Ameliorates Manifestations of Pneumonia in Established Novel Coronavirus Infection (COVID-19) Recruiting Phase 2 Nov/18/2020 Feb/01/2022
  • Alternative id - STUDY00000701
  • Interventions - Drug: Duvelisib|Drug: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Emory Saint Joseph's Hospital, Atlanta, Georgia, United States|Emory University Hospital Midtown, Atlanta, Georgia, United States|Emory University Hospital, Atlanta, Georgia, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment
  • Enrollment - 80
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Number of Participants Requiring Mechanical Ventilation or Dying|Days to Recovery|Duration of Hospitalization|Incidence of Death|Proportion of Participants Transferred to ICU|Change in Eastern Cooperative Oncology Group (ECOG) Performance Status Score|Incidence of Grade III-V Adverse Events|Incidence of Secondary Bacterial or Viral Infections|Change in Th1 T Cell Frequency|Change in Th17 T Cell Frequency|Change in Interleukin-2 (IL-2)|Change in Interleukin-2 receptor (IL-2R)|Change in Interleukin-6 (IL-6)|Change in Interleukin-7 (IL-7)|Change in Interleukin-8 (IL-8)|Change in Interleukin-10 (IL-10)|Change in Interferon gamma-induced Protein 10 (IP-10)|Change in Macrophage Inflammatory Protein 1alpha (MIP-1a)|Change in Monocyte Chemoattractant Protein-1 (MCP-1)|Change in Granulocyte Colony-stimulating Factor (G-CSF)|Change in Tumor Necrosis Factor (TNF)-alpha|Change in Vasoactive Intestinal Peptide (VIP)|Change in Gene Expression Profile of Regulatory T Cells (Tregs)|Change in Gene Expression Profile of cluster of differentiation 8 (CD8)+Interferon Gamma (IFNg)+ Granulocyte-macrophage colony-stimulating factor (GM-CSF)+|Change in Gene Expression Profile of CD8+ T cell immunoglobulin and mucin domain-containing protein 3 (Tim3)+ Programmed cell death protein 1 (PD-1)+|Change in Gene Expression Profile of cluster of differentiation 14 (CD14)+ cluster of differentiation (CD16)+ monocytes|Change in SARS-CoV-2 Viremia|Change in Immunoglobulin G (IgG) Antibodies|Change in Immunoglobulin M (IgM) Antibodies|Overall Survival
NCT04371978 Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19 Terminated Phase 3 Oct/01/2020 May/04/2021
  • Alternative id - 0303-20-RMC
  • Interventions - Drug: Linagliptin 5 MG
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Shamir Medical Center, Be'er Ya'aqov, Israel|Rabin Medical Center, Beilinson Campus, Petah tikva, Israel|Rabin Medical Center, Hasharon Campus, Petah tikva, Israel
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 64
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Time to clinical change|Percent of serious adverse events and premature discontinuation of treatment.|Percent of patients with clinical improvement.|Length of hospitalization.|All-cause mortality.|Percent of supplemental oxygen use.|Supplemental oxygen-free days.|Percent of mechanical ventilation use.|Ventilator-free days.|Percent of ICU admissions.|ICU-free days.|Percent of 50% decrease in C-reactive protein (CRP) levels|Time to virologic response, defined as no detection of SARS-CoV-2 in a PCR test.
NCT04365530 Become of Patients Infected or Suspected of Being Infected by Covid-19 and Supported by the GHPSJ and the Establishments of the Paris Plaisance Hospital City Recruiting Apr/01/2020 Dec/31/2022
  • Alternative id - Cohorte COVID GHPSJ CiteH
  • Interventions -
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Hôpital Marie Lannelongue, Le Plessis-Robinson, France|AURA Paris Plaisance, Paris, France|Fondation Sainte-Marie, Paris, France|Groupe Hospitalier Paris Saint-Joseph, Paris, France|Hôpital Bellan, Paris, France
  • Study designs - Observational Model: Cohort|Time Perspective: Other
  • Enrollment - 2000
  • Age - Child, Adult, Older Adult
  • Outcome measures - Clinical consequences of a Covid-19 infection in the care population|Risk factors at M6|Risk factors at year 1|Risk factors at year 2|Impact of hospital reorganization on medical care at M6|Impact of hospital reorganization on medical care at Year 1|Impact of hospital reorganization on medical care at Year 2
Export (.csv)